Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its ...

I n a challenging year for Actinium Pharmaceuticals (NYSE:ATNM), the company's stock has touched a 52-week low, trading at $1.1, marking an 80% decline from its 52-week high of $10.24. According ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Actinium-225 offers a different approach by using alpha particles instead of beta particles. Alpha particles are highly energetic and travel only a short distance, which allows them to effectively ...

Actinium Pharmaceuticals (ATNM) announced that the first clinical trial under its previously announced Cooperative Research and Development Agreement with the National Cancer Institute for Actimab ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration with ...

Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bolstering the case for the ...

At the forefront of this development is Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing ARCs. It uses use internal radiation to fight cancer, by linking a ...

Actinium is a clinical-stage biopharmaceutical company that has devised an innovative strategy to overcome these hurdles. The company is leveraging its Antibody Warhead Enabling (AWE) technology ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), whose stock has declined over 83% in the past year according to InvestingPro data, has launched a clinical trial in collaboration ...